BioNxt Solutions (CSE:BNXT; OTC:BNXTF; FSE:BXT) has announced that it will transition its research and development activities to Gen-Plus, a contract research and development organization in Munich, Germany, effective March 1, 2025.
The company anticipates that the move will accelerate its ongoing projects in drug delivery systems, neurodegenerative disease therapies, and next-generation biomedical technologies. According to BioNxt, the Gen-Plus 1,000-square-meter laboratory is equipped for high-potency active pharmaceutical ingredients and GMP-compliant processes. Its specialized equipment includes advanced technology for solid and semi-solid dosage forms, and capabilities in drug printing.
“BioNxt’s transition to Gen-Plus marks a pivotal moment for BioNxt,” Hugh Rogers, CEO of BioNxt commented. “This transition is both strategic and timely, and unlocking new possibilities for added strength on IP with innovation and reinforcing our mission to deliver transformative therapies for patients worldwide. We are thrilled about the opportunities.”
